In pharmaceutical marketing, the gap between what a platform promises and what it delivers is rarely made visible. Reach figures are quoted, campaigns run and the true efficiency of the audience reached is seldom scrutinised in detail.
A case study from one European market makes that gap impossible to ignore.
The scenario
A €100,000 campaign targeting 20,000 Spanish doctors. Two platforms. Two very different approaches to audience verification. Two very different outcomes.Why the distinction matters
The practical consequence of this spectrum is significant. Analysis of one European HCP platform revealed that out of 112,987 total accounts, only 60% (67,811) were fully validated. Of those, only 57.85% had been active within the last 365 days.
For a pharmaceutical marketer running a campaign against that database, the effective verified active reach is less than 35% of the headline figure. The CPM quoted bears almost no relationship to the CPM actually paid to reach a verified, active doctor.
Platform A – industry standard (total database reporting)
The platform quotes a reach of 20,000 doctors. The campaign runs. Post-campaign analysis reveals the reality: of the 20,000 accounts in the database, only 11,570 were verified and active within the last 365 days. The remaining 8,430 – 42.15% of the quoted audience – were inactive, unverified, or both.
The hidden waste on that campaign: €42,150. More than two-fifths of the budget spent reaching an audience that wasn’t meaningfully there.
Platform B – gold-standard verified active reporting (M3 Vademecum)
The platform quotes a reach of 11,570 verified active doctors – because that is the verified active reach. The campaign runs against that audience. The actual reach: 11,570. The waste: €0.
The same doctors. The same budget. A €42,150 difference.
The doctors reached by both campaigns were, ultimately, the same people – the 11,570 verified active Spanish physicians. The difference was not in the audience itself, but in how each platform reported and charged for it.
Platform A charged for 20,000 and delivered 11,570. Platform B charged for 11,570 and delivered 11,570. The transparency of the reporting – and the rigour of the verification behind it – is the entire difference.
The data behind the numbers
The Vademecum platform’s verification data for this market provides a detailed picture of what gold-standard verification looks like in practice:
- Out of 112,987 total accounts, 67,811 were fully validated (60%)
- 57.85% were active within the last 365 days; 42.14% were inactive for 12 months or more
- Of 3,243 registration attempts, 50.42% were immediately validated; only 1.79% failed
These are not aspirational targets. They are the operational standards applied as a matter of course – the result of a verification framework built around official registry partnerships, automated credential checking and systematic data cleansing.
What this means at scale
The Spain case study involves a €100,000 campaign. Scale that dynamic to the typical pharmaceutical marketing investment – HCP digital marketing spend per treatment ranges from $5 million to $30 million or more – and the cumulative impact of verification gaps becomes very significant indeed.
If 42% of the audience on a $10 million HCP digital campaign is inactive or unverified, the effective waste is not a rounding error. It is a material commercial problem with direct consequences for campaign ROI, strategic decision-making and ultimately, the commercial success of the treatment being promoted.
The broader verification picture
The Spain data also illustrate a point that applies across markets. The problem is not unique to any one country or platform – it is a function of industry-standard practices that have become normalised: self-reported credentials, infrequent database cleansing and reach-reporting based on total database size rather than verified active users.
For UK pharmaceutical marketers, the equivalent question is straightforward: of the doctors your platform quotes as reach, how many are GMC-verified and active in the last 365 days? On Doctors.net.uk – part of the M3 Group – every one of the 270,000+ members is GMC-verified. The reach figure quoted is the reach figure delivered.
The case for transparency
The Spain case study is ultimately a case for transparency. A platform that reports verified active reach rather than total database size is not offering a smaller audience – it is offering an honest one. And in pharmaceutical marketing, where every pound of budget must demonstrate ROI and every campaign decision has downstream commercial consequences, an honest audience is worth considerably more than an inflated one.
The €42,150 saved on that single Spanish campaign is not a hypothetical saving. It is the direct, measurable result of a platform that built its business around verified reach – and reports it that way.
Download The Hidden Cost of Unverified Audiences white paper
*Data was acquired by Vademecum, part of the Vidal Group which is part of the M3 Group.
